INT8600

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 1992
Last Reported 2007
Negated 1
Speculated 0
Reported most in Abstract
Documents 6
Total Number 7
Disease Relevance 0.87
Pain Relevance 3.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Nkx2-2) nucleus (Nkx2-2) molecular_function (Nkx2-2)
transcription factor binding (Nkx2-2)
Nkx2-2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
substance P 99 100.00 Very High Very High Very High
antagonist 10 100.00 Very High Very High Very High
qutenza 15 98.86 Very High Very High Very High
Potency 5 97.68 Very High Very High Very High
Dopamine 8 95.76 Very High Very High Very High
Neuropeptide 19 95.28 Very High Very High Very High
Spinal cord 22 92.88 High High
Opioid 11 88.48 High High
Central nervous system 9 82.32 Quite High
Pain 3 77.68 Quite High
Disease Link Frequency Relevance Heat
Vibrio Infection 40 85.04 High High
Nociception 22 83.00 Quite High
Pain 3 77.68 Quite High
Cv Unclassified Under Development 1 67.12 Quite High
Hypoxia 1 66.08 Quite High
Hyperalgesia 16 38.16 Quite Low
Hypersensitivity 2 16.00 Low Low
Injury 4 5.00 Very Low Very Low Very Low
Overdose 2 5.00 Very Low Very Low Very Low
Diphtheria 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pretreatment with CGRP 8-37 (CGRP receptor antagonist) and NK-1 but not NK-2 nor NK-3 receptor antagonists significantly reduced the HABF by 43% (p< 0.05) and 25% (p< 0.05) as compared to the HABF value in the control HABR group.
NK-2 Binding (Pretreatment) of associated with antagonist
1) Confidence 0.10 Published 2005 Journal J. Physiol. Pharmacol. Section Abstract Doc Link 15795481 Disease Relevance 0.13 Pain Relevance 0.42
It did not interact with the two other tachykinin receptor sites (NK2 and NK3) nor the other receptor sites tested.
NK2 Neg (not) Binding (interact) of
2) Confidence 0.09 Published 1992 Journal C. R. Acad. Sci. III, Sci. Vie Section Abstract Doc Link 1376187 Disease Relevance 0.05 Pain Relevance 0.40
The NK-1, NK-2 and NK-3 receptor ligands [Sar9, Met(O2)11]SP, R396 and senktide, respectively, showed no or negligible binding.
NK-2 Binding (binding) of associated with substance p
3) Confidence 0.08 Published 2006 Journal Peptides Section Abstract Doc Link 16216386 Disease Relevance 0.30 Pain Relevance 1.22
The present study performed with SR48968 (10(-6) M) to avoid any interaction of the tested peptides with NK2 receptors, indicates that substance P(6-11) (with a high potency), neurokinin A, neurokinin B and to a lesser extent neuropeptide K (with a lower potency) stimulate [3H]-inositol monophosphate ([3H]-IP1) formation in this tissue by acting on the 'septide-sensitive' tachykinin receptors.
NK2 Binding (interaction) of associated with neuropeptide, potency and substance p
4) Confidence 0.07 Published 1997 Journal Neuropeptides Section Abstract Doc Link 9243521 Disease Relevance 0 Pain Relevance 0.32
However, if the NK1 receptors do not rapidly recycle to the cell surface the NK2 receptors will eventually bind and internalize an equal amount of SP-CTA.
NK2 Binding (bind) of
5) Confidence 0.01 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1878491 Disease Relevance 0.14 Pain Relevance 0.20
These data suggest that the conjugate binds to NK1 and NK2 receptors with approximately the same affinity.
NK2 Binding (binds) of
6) Confidence 0.01 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1878491 Disease Relevance 0.24 Pain Relevance 0.23
N-arachidonoyl-dopamine exerted a potent contractile response of guinea pig isolated bronchi (EC50=12.6 +/- 1.7 microM, Emax=69.2 +/- 2.4% of carbachol Emax), which was blocked by pre-treatment with capsaicin or with the VR1 antagonist capsazepine, as well as by a combination of tachykinin NK1 and NK2 receptor antagonists.
NK2 Binding (combination) of associated with dopamine, qutenza and antagonist
7) Confidence 0.01 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12954366 Disease Relevance 0 Pain Relevance 1.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox